110 related articles for article (PubMed ID: 37805292)
1. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging.
Vinje CA; Vigmostad MN; Kjosavik SR; Grönberg H; Gilje B; Skeie S
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37805292
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
4. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
5. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
[TBL] [Abstract][Full Text] [Related]
6. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.
Wagensveld IM; Osses DF; Groenendijk PM; Zijta FM; Busstra MB; Rociu E; Barentsz JO; Michiel Sedelaar JP; Arbeel B; Roeleveld T; Geenen R; Koeter I; van der Meer SA; Cappendijk V; Somford R; Klaver S; Van der Lely H; Wolters T; Hellings W; Leter MR; Van der Poel HG; Heijmink SWTPJ; Debruyne F; Immerzeel J; Leijte J; van Roermund J; Miclea R; Planken E; Vis AN; Jan de Jong I; Tijsterman J; Wolterbeek D; Claessen A; Vrijhof E; Nederend J; Van Leenders GJLH; Bangma CH; Krestin GP; Remmers S; Schoots IG;
Eur Urol; 2022 Sep; 82(3):318-326. PubMed ID: 35341658
[TBL] [Abstract][Full Text] [Related]
9. Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
Andersson J; Palsdottir T; Lantz A; Aly M; Grönberg H; Egevad L; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Oct; 44():69-75. PubMed ID: 36185581
[TBL] [Abstract][Full Text] [Related]
10. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
11. Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort.
Elyan A; Saba K; Sigle A; Wetterauer C; Engesser C; Püschel H; Attianese S; Maurer P; Deckart A; Cathomas R; Strebel RT; Gratzke C; Seifert HH; Rentsch CA; Mortezavi A
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37813730
[TBL] [Abstract][Full Text] [Related]
12. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
13. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.
Palsdottir T; Söderbäck H; Jäderling F; Bergman M; Vigneswaran H; Grönberg H
Eur Urol Open Sci; 2024 Mar; 61():29-36. PubMed ID: 38384438
[TBL] [Abstract][Full Text] [Related]
14. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
15. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
[TBL] [Abstract][Full Text] [Related]
16. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
[TBL] [Abstract][Full Text] [Related]
17. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Machado A; Levental M; Ghai S; Chang SD; Patel C; Kassam Z; Loblaw A; Kebabdjian M; Pond G; Haider MA
Eur Urol Oncol; 2024 Jun; 7(3):456-461. PubMed ID: 37838556
[TBL] [Abstract][Full Text] [Related]
19. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
Olsson H; Nordström T; Jäderling F; Egevad L; Vigneswaran HT; Annerstedt M; Grönberg H; Eklund M; Lantz A
J Natl Cancer Inst; 2021 May; 113(5):632-640. PubMed ID: 32866231
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
